Floatz logo

Zanubrutinib

Splenic B-cell Lymphoma/Leukaemia With Prominent Nucleoli，SBLPN

Institute of Hematology & Blood Diseases Hospital, ChinaSmall moleculePhase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
95/ 100

Competitive context

2 Active assets in the Splenic B-cell Lymphoma/Leukaemia With Prominent Nucleoli，SBLPN cohort.

Asset / SponsorPhaseRating
Obinutuzumab
Institute of Hematology & Blood Diseases Hospital, China
Phase 2CCC
cc-5013
Institute of Hematology & Blood Diseases Hospital, China
Phase 2CCC

Same molecule, other indications

Zanubrutinib is also rated in:

B-cell non-Hodgkin lymphomaDormant
BBB
Indicative ·
73 / 100
View asset →
splenic marginal zone lymphomaDormant
BB
Indicative ·
68 / 100
View asset →
marginal zone lymphomaDormant
BB
Indicative ·
67 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →